Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Corcept Therapeutics Inc banner

Corcept Therapeutics Inc
SWB:HTD

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
SWB:HTD
Watchlist
Price: 80.64 EUR -1.9%
Market Cap: €5.5B
Write Note Create Alert Ask AI

Wall St Price Targets

HTD Price Forecast
Based on 7 analysts

+76% Upside
from €80.64 today

HTD Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for HTD yet.

Corcept Therapeutics Inc Competitors:
Price Targets

Revenue
Forecast

52% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
52% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 52%. The projected CAGR for the next 8 years is 20%.

What are analyst estimates?

Gross Profit
Forecast

52% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
52% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 52%. The projected CAGR for the next 8 years is 20%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
65% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
65% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

The compound annual growth rate for Operating Income over the next 8 years is 65%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
158% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
158% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

The compound annual growth rate for Pre-Tax Income over the next 3 years is 158%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
46% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
46% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

The compound annual growth rate for Net Income over the next 8 years is 46%.

What are analyst estimates?

Continue HTD Research

Summary
HTD intrinsic value, competitors valuation, and company profile.
DCF Valuation
HTD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HTD stock valuation using valuation multiples.
Wall St Estimates
HTD price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HTD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Corcept Therapeutics Inc listings:
NASDAQ • USD
CORT
 F • EUR
HTD
 XMUN • EUR
HTD
 LSE • USD
0I3Q
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is HTD's stock price target?
Price Target
142.05 EUR

According to Wall Street analysts, the average 1-year price target for HTD is 142.05 EUR with a low forecast of 43.28 EUR and a high forecast of 148.47 EUR.

What is the Revenue forecast for Corcept Therapeutics Inc?
Projected CAGR
20%

Over the last 13 years, the compound annual growth rate for Revenue has been 52%. The projected CAGR for the next 8 years is 20%.

What is the Gross Profit forecast for Corcept Therapeutics Inc?
Projected CAGR
20%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 52%. The projected CAGR for the next 8 years is 20%.

What is the Operating Income forecast for Corcept Therapeutics Inc?
Projected CAGR
65%

The compound annual growth rate for Operating Income over the next 8 years is 65%.

What is the Pre-Tax Income forecast for Corcept Therapeutics Inc?
Projected CAGR
158%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 158%.

What is the Net Income forecast for Corcept Therapeutics Inc?
Projected CAGR
46%

The compound annual growth rate for Net Income over the next 8 years is 46%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.